Northwest Biotherapeutics Files 8-K

Ticker: NWBO · Form: 8-K · Filed: 2024-08-02T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, regulation-fd

Related Tickers: NWBO

TL;DR

NWBO filed an 8-K for a Reg FD disclosure. No specific details yet.

AI Summary

Northwest Biotherapeutics, Inc. filed an 8-K on August 2, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.

Why It Matters

This filing indicates Northwest Biotherapeutics is making a public disclosure, which could contain important information for investors, though the details are not specified in this summary.

Risk Assessment

Risk Level: medium — The filing is a standard disclosure, but the lack of specific details about the nature of the Regulation FD disclosure warrants a medium risk assessment.

Key Players & Entities

FAQ

What is the specific nature of the Regulation FD Disclosure being made by Northwest Biotherapeutics?

The provided text does not specify the content of the Regulation FD Disclosure, only that one is being made.

Has Northwest Biotherapeutics announced any new material events or agreements in this filing?

The filing is categorized as a Regulation FD Disclosure, and no other specific material events are detailed in the provided text.

What is the principal executive office address for Northwest Biotherapeutics?

The principal executive offices are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.

What is the IRS Employer Identification Number for Northwest Biotherapeutics?

The IRS Employer Identification Number is 94-3306718.

What is the filing date of this 8-K report?

The report was filed on August 2, 2024.

Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-08-02 10:42:28

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Over the last several days, NWBio has received inquiries and messages from a number of shareholders regarding several rumors being passed around social media platforms relating to our business outlook. Some of the shareholder messages have identified a potential connection between these rumors and certain parties associated with the lawsuit we are currently pursuing in federal court in NY. While it is our standard practice not to comment on rumors, we have noted the coincidence of timing between these rumors and certain developments in the market relating to our stock. We are investigating the source(s) of these rumors and we plan to pursue appropriate action. We request that our shareholders continue to send us any information related to the rumors, the parties who are spreading them, and related matters. We also ask that our shareholders and all interested parties carefully consider the source(s) of rumors, their reliability and their self-interests before forming a judgment about them. There are several high profile court cases pending that involve the use of these types of tactics in order to negatively impact a company's stock, and high profile civil and criminal enforcement actions in this arena have recently commenced. We advise caution in evaluating rumors. Meanwhile, we are continuing to focus on working with our teams of consultants on activities related to the review by the Medicines and Healthcare Products Regulatory Agency (MHRA) of our Marketing Authorization Application (MAA) in the UK, including preparations for inspections by the MHRA that are scheduled to take place in both the US and UK. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: August 2, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executi

View on Read The Filing